GlycoMimetics Inc reports results for the quarter ended in December - Earnings Summary

Crescent Biopharma

27/03/2024 13:32

* GlycoMimetics Inc  GLYC.OQ  reported a quarterly adjusted
loss
of 14 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -19 cents.  The mean expectation of
four analysts for the quarter was for a loss of 15 cents per
share. Wall Street expected results to range from -16 cents
to -15 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GlycoMimetics Inc's reported EPS for the quarter was a
loss
of 14 cents​.
    * The company reported a quarterly loss of $9.08 million.
    * GlycoMimetics Inc shares had risen by 20.8% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for GlycoMimetics Inc
is $8.00 
This summary was machine generated from LSEG data March 27 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.15          -0.14          Beat
 Sep. 30 2023      -0.14          -0.14          Met
 Jun. 30 2023      -0.18          -0.13          Beat
 Mar. 31 2023      -0.17          -0.17          Met